Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...
Researchers from Zjengzhou University reported on the discovery and preclinical characterization of a novel proteolysis targeting chimera (PROTAC) agent aimed at overcoming paclitaxel (Taxol) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback